Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma.

ABSTRACT:

Background

Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established markers to monitor for evolving CVD during treatment. New possibilities have arisen with the emergence of newer techniques allowing for analysis of plasma proteins that can be associated with cardiovascular disease. Proximity Extension Assay is one of them.

Objectives

We aimed to illustrate the incidence of CVD in DLBCL patients treated with DXR and to establish whether there are plasma proteins associated with pre-existing or emerging CVD.

Methods

In 95 patients, 182 different prote

SUBMITTER: Morth C 

PROVIDER: S-EPMC7856776 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature